Over 10 yrs ago, we generated the mouse oral carcinoma (MOC) #HNSCC cell lines. Dr. Kono(H&N surgeon #asahikawa #旭川医科大学) reviews nearly 100 studies to date using MOC lines (authors.elsevier.com/a/1fNqY4tFDIGH…). Thx to Dr. Clint Allen/all in my lab/so many others.

Excited to share our data for preventative immunotherapy in high risk oral precancerous disease ESMO - Eur. Oncology #ESMO2022 on 9/12 -- Alessandro Villa, DDS, PhD, MPH Sookbin Woo Dana-Farber Dana-Farber News

Grateful to ⁦Robert Haddad⁩ & colleagues ⁦Dana-Farber⁩ ⁦Brown University⁩ ⁦Geisel School of Medicine at Dartmouth⁩ ⁦⁦UCSF School of Medicine⁩ ⁦KU Medical Center⁩ peripheral blood biomarkers of response to aPD-1 in R/M #HNSCC #ESMO2022 ⁦ESMO - Eur. Oncology⁩ ⁦⁦Dana-Farber News⁩

What are Natural Killer Cells? blog.dana-farber.org/insight/2022/0…

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651 ascopubs.org/doi/pdf/10.120… Nabil Saba, MD Ravi Uppaluri, MDPhD Ezra Cohen R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) Sana Karam, MD, PhD

Thank you TIME for allowing me to highlight the importance of clinical trials in Kidney Cancer! We have come a long way, but still a lot to do! time.com/6241441/kidney… Dana-Farber Dana-Farber Lank Center for Genitourinary Oncology OncoAlert Dana-Farber News DF/HCC Victoria Warren G O L D I E.

Our Phase III Kestrel is out: Durva with or without tremelimumab versus EXTREME regimen as first-line treatment for recurrent HNC: No difference between arms, high crossover to IO in EXTREME Annals of Oncology Nabil Saba, MD Robert Ferris, MD, PhD Ezra Cohen R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) AstraZeneca

Excited to share our paper on the first small molecule inhibitors of PTPN2/PTPN1 for cancer immunotherapy out today in nature nature.com/articles/s4158… This has been a collaboration with Calico and AbbVie. Very proud of the amazing team that made this happen! Explainer below👇

#CCTI_DFCI For #trialtuesday, learn more about DF/HCC 17-343 led by Dr. Geoff Shapiro. Open for solid tumors with cyclin D2/3 amps or cyclin D1 mutations studying a CDK4/6 inhibitor. This study seeks to expand CDK4/6 inhibitors beyond breast cancer! Visit forms.office.com/r/kM7e6JVxre

Excited to support our outstanding DFCI colleagues for these ASCO leadership positions! Toni Choueiri, MD Kimmie Ng, MD, MPH Abby Rosenberg, MD, MS, MA

Our Dana-Farber and The Jimmy Fund during the holidays! #youhaveus #hope #beatKancer

David Leaf Jamie Hirsch Kenar Jhaveri meg sise Wenxin (Vincent) Xu Matthew Abramson Kartik Sehgal Kerry Reynolds Don Chute Shveta Motwani American Society of Onconephrology Brigham and Women’s Research

David Leaf AnIpB Don Chute Shveta Motwani Matthew Abramson Wenxin (Vincent) Xu Kerry Reynolds Kenar Jhaveri Jamie Hirsch meg sise MGH Onconephrology @kartiksehgal_md

Excited to share our npj Journals paper on methylation cytometry blood profiles associating with immunotherapy response in head and neck cancer. Kudos to the team Dartmouth Cancer Center Dana-Farber Brock Christensen Lucas Salas Kartik Sehgal Robert Haddad!🧬nature.com/articles/s4169…

We’re thrilled to announce the launch of Center for RAS Therapeutics to target the RAS oncogene in cancer. The first of its kind Center aims to advance new treatment approaches for patients with RAS mutant cancers. Learn more: bit.ly/3BobmtB

.Dana-Farber announced the Center for RAS Therapeutics, an initiative that aims to advance new treatments for patients with RAS-mutant cancers through collaborations between researchers, industry, and other academic medical centers. ➡️ bit.ly/3DIgdqi

Thoracic Medical Oncology BIDMC Team Thoracic Park demonstrating the scientific and clinical innovation, hope, and humility needed to advance the care of our lung cancer patients in all of the ways that they need. Grateful for this team of thinkers and doers. BIDMC Cancer Center BIDMC Hematology/Oncology Fellowship

Head and neck cancer study shows immunotherapy improved outcomes in patients in curative setting. Dana-Farber Principal Investigator Robert Haddad discusses the Phase 3 KEYNOTE-689 study presented at #AACR25 by Ravi Uppaluri, MDPhD (Dana-Farber & Brigham and Women's Hospital)